NK-92/5.28.z cells also killed trastuzumab-sensitive and trastuzumab-resistant ErbB2-positive breast carcinoma cells to a similar extent (Figure 2), attesting to the different mode of action of the retargeted NK cells and suggesting their application in a disease setting with existing resistance to other targeted therapies. This evidence concerns the gene ERBB2 and breast carcinoma.